

Extensive Focal Epithelial Hyperplasia: Case Report

Braz Campos Durso, DDS, MSD; José Marcelo Vargas Pinto, DDS; Jacks Jorge Jr, DDS, PhD; Oslei Paes de Almeida, DDS, PhD

Contact Author

Dr. Durso
E-mail: patologiabucal@yahoo.com.br



ABSTRACT

Focal epithelial hyperplasia (FEH) is a rare benign lesion caused by human papillomavirus subtype 13 or 32. The condition occurs in numerous populations and ethnic groups. A higher incidence in close communities and among family members indicates infectious pathogenesis. A 21-year-old woman with FEH is described, in whom the lesions had persisted for 10 years. A literature review is also presented, with emphasis on manifestations in the oral mucosa and histopathological features.

MeSH Key Words: case report; focal epithelial hyperplasia; papillomavirus, human

© J Can Dent Assoc 2005; 71(10):769–71
This article has been peer reviewed.

Focal epithelial hyperplasia (FEH) is a rare benign lesion^{1,2} caused by human papillomavirus (HPV)^{1–5} subtype 13 or 32.^{1,4–7} Factors that have been associated with this disease include communal lifestyle, poor hygiene and poverty.^{6–8}

FEH is found in numerous geographic populations and ethnic groups such as North, South and Central American Indians,^{1–10} but is rare among white people.^{1,3,4,7} It is characterized by multiple soft, circumscribed, sessile nodules of whitish colour or a colour similar to the adjacent oral mucosa,^{1,10} affecting the lips, the cheek mucosa^{2,4,6} and the lateral borders of the tongue.^{2,6}

A high incidence in close communities and among family members indicates infectious pathogenesis.⁵

This report is intended to educate and inform general dental practitioners, so that they may be able to recognize, diagnose and manage FEH in their own patients.

Case Report

A 21-year-old woman attended the Stomatology Clinic of São Lucas Dental School

with “lumps throughout the mouth and throat and fear of having cancer.” She reported that the lesions, which were painless to palpation, had appeared spontaneously 10 years before and that she had already taken several drugs, with no success. The patient was of South American Indian descent and did not report any other systemic disturbance. The results of serological tests were unremarkable. Oral examination revealed several sessile, normochromic tissue proliferations on the cheek mucosa, lip mucosa and tongue (Figs. 1 and 2). Areas of lymphoid hyperplasia were observed in the patient’s throat. The lesions were soft, similar in colour to the normal mucosa, and of variable diameter. The clinical diagnosis was FEH, and incisional biopsy was performed on the cheek and lip mucosa. Microscopic examination by the Pathological Anatomy Service revealed hyperkeratinized stratified epithelium exhibiting hyperplasia and deep papillomatous projections. Some squamous cells exhibited mitotic figures, called mitosoid cells (Fig. 3). The underlying connective tissue was well supplied with collagen and well vascularized, with some congested vessels. The patient was



Figure 1: Labial mucosa of a 21-year-old woman shows multiple slightly elevated papulonodular lesions, typical of oral lesions of focal epithelial hyperplasia due to human papillomavirus.



Figure 2: Lesions were also seen on the patient's lip mucosa and tongue.




Figure 3: Photomicrograph demonstrates acanthosis, parakeratosis and epithelial hyperplasia; there is a lack of inflammatory response, and koilocytic cells with perinuclear halo are visible within the epithelium. Hematoxylin and eosin; original magnification $\times 40$.

informed of the benign nature of the lesions, which were not removed because of their large number. The patient was followed for one year, during which no clinical alteration of the lesions was observed. After this period, the patient moved to another city and was lost to follow-up.

Discussion

Information about the natural history of FEH is still incomplete.⁷ Some lesions may persist to adulthood without spontaneous regression,¹⁰ as in this patient, in whom the lesions had persisted for 10 years.

The erratic clinical course of the disease, with the lesions varying in size, number, period of regression and pattern of onset, is comparable to that of some other HPV infections.⁷ It is an open question whether this variation indicates different levels of infection or different levels of immune response.⁷

Dos Santos and others⁸ stated that FEH was the most prevalent lesion of the oral mucosa among Waimiri Atoari Indians, reaching 21% with no differences between the sexes or among different age groups. Younger patients with FEH had multiple lesions, which were predominantly nodular, whereas older patients had few or even single lesions, which tended to be flat and papular.

The diagnosis of FEH can be made on the basis of clinical observations,^{1,4} but histological examination may show characteristics of viral infection,¹ as reported here.

FEH may be associated with HIV infection,^{3-4,10} although the relationship between these 2 conditions has not yet been completely clarified.⁴ Suppression of the immune system leaves the patient vulnerable to opportunistic infections,³⁻⁴ including HPV infections.⁴ It should be remembered that oral lesions are not always pathognomonic of underlying systemic conditions.² As such, a thor-

ough physical examination and other appropriate investigations should be carried out to establish the definitive diagnosis.² Moerman and others⁴ stated that FEH lesions may have a great risk of malignant transformation in immunocompromised patients. However, the present authors believe that this statement is misleading, given that FEH is considered a benign condition. Many immunocompromised patients do develop many HPV lesions, some of which are caused by HPV subtypes with so-called high-risk for malignancy (such as 18, 31, 33, 35 and 51). Although current research has shown no malignant potential for FEH lesions associated with HPV 13 and 32 subtypes in immunocompromised patients, further studies are required.

A previous report⁶ suggested the need for serial sectioning of FEH lesions to allow identification of mitotic cells, which may not be present in single sections.

First-line therapies for FEH include surgical or cryosurgical procedures, electrocoagulation or treatment with carbon dioxide laser.³⁻⁵ However, these invasive therapies have more risks and side effects than topical treatment.⁵

Steinhoff and others⁵ stated that therapy with interferon- β appears to be a simple, effective, noninvasive and low-risk alternative to invasive or surgical modalities. However, its efficacy in the treatment of oral lesions has not been adequately tested. The case documented by Steinhoff and others⁵ represented an unusual FEH condition that required unique treatment, and the patient was followed for only 7 months, a relatively short time for a persistent viral condition such as FEH. Furthermore, in a cost analysis of various treatments for non-genital warts, Clemons and others⁹ observed that the least expensive

therapy was CO₂ laser ablation. Because FEH lesions may spontaneously appear and disappear, the dentist should inform the patient of the benign nature of the lesion and then perform treatment or offer follow-up in accordance with the patient's preferences.

It is impossible to predict when and if FEH lesions will recur or where new lesions may emerge; therefore, continued follow-up is necessary.³ It is not known whether recurrence of the lesions is related to latent infection, changes in immune response or new infections.⁷ ➤

THE AUTHORS



Dr. Durso is a professor and chair of stomatology at the São Lucas Dental School, Rondônia, Brazil.



Dr. Pinto is a professor of oral surgery at the São Lucas Dental School, Rondônia, Brazil.

Dr. Jorge is a professor of oral pathology at the Piracicaba Dental School, São Paulo, Brazil.

Dr. de Almeida is a professor and chair of oral pathology at the Piracicaba Dental School, São Paulo, Brazil.

Correspondence to: Dr. Braz Campos Durso, Rua Alexandre Guimarães 1927, Bairro Areal, Porto Velho – RO, CEP 78916-450, Brazil. E-mail: patologiabucal@yahoo.com.br.

The authors have no declared financial interests.

References

1. Bassioulas K, Danielides V, Georgiou I, Photos E, Zagorianakou P, Skevas A. Oral focal epithelial hyperplasia. *Eur J Dermatol* 2000; 10(5): 395–7.
2. Chindia ML, Awange GO, Guthua SW, Mwaniki DL. Focal epithelial hyperplasia (Heck's disease) in three Kenyan girls: case reports. *East Afr Med J* 1993; 70(9):595–6.
3. Marvan E, Firth N. Focal epithelial hyperplasia in an HIV positive man. An illustrated case and review of the literature. *Aust Dent J* 1998; 43(5):305–10.
4. Moerman M, Danielides VG, Nousia CS, Van Wanzele F, Forsyth R, Vermeersch H. Recurrent focal epithelial hyperplasia due to HPV13 in an HIV-positive patient. *Dermatology* 2001; 203(4):339–41.
5. Steinhoff M, Metz D, Stodefleth E, Luger TA. Successful topical treatment of focal epithelial hyperplasia (Heck's disease) with interferon-beta. *Br J Dermatol* 2001; 144(5):1067–9.
6. Carlos R, Sedano HO. Multifocal papilloma virus epithelial hyperplasia. *Oral Surg Oral Med Oral Pathol* 1994; 77(6):631–5.
7. Harris AMP, van Wyk CW. Heck's disease (focal epithelial hyperplasia): a longitudinal study. *Community Dent Oral Epidemiol* 1993; 21(2):82–5.
8. dos Santos PJ, Bessa CF, de Aguiar MC, do Carmo MA. Cross-sectional study of oral mucosal conditions among a central Amazonian Indian community, Brazil. *J Oral Pathol Med* 2004; 33(1):7–12.
9. Clemons RJ, Clemons-Miller A, Johnson SM, Williamson SK, Horn TD. Comparing therapy costs for physician treatment of warts. *J Drugs Dermatol* 2003; 2(6):649–54.
10. Jayasooriya PR, Abeyratne S, Ranasinghe AW, Tilakaratne WM. Focal epithelial hyperplasia (Heck's disease): report of two cases with PCR detection of human papillomavirus DNA. *Oral Dis* 2004; 10(4):240–3.